tooluniverse-adverse-event-detection by mims-harvard/tooluniverse
npx skills add https://github.com/mims-harvard/tooluniverse --skill tooluniverse-adverse-event-detection使用 FAERS 不成比例分析、FDA 标签挖掘、基于机制的预测和文献证据,自动检测、量化和情境化药物不良事件信号的流程。为监管和临床决策生成量化的安全信号评分(0-100)。
核心原则:
参考文件(位于此目录):
PHASE_DETAILS.md - 每个阶段的详细工具调用、代码示例和输出模板REPORT_TEMPLATE.md - 完整的报告模板和完整性检查清单TOOL_REFERENCE.md - 工具参数参考和备用链QUICK_START.md - 快速示例和常见药物名称广告位招租
在这里展示您的产品或服务
触达数万 AI 开发者,精准高效
当用户询问以下问题时应用:
与 tooluniverse-pharmacovigilance 的区别:此技能专门侧重于使用不成比例分析(PRR、ROR、IC)进行信号检测和量化,具有统计严谨性,生成量化的安全信号评分(0-100),并在药物类别间进行比较安全性分析。
Phase 0: 输入解析与药物消歧
解析药物名称,解析为 ChEMBL ID、DrugBank ID
识别药物类别、作用机制和获批适应症
|
Phase 1: FAERS 不良事件概况分析
按频率排序的顶级不良事件
严重性和结果分布
人口统计学(年龄、性别、国家)
|
Phase 2: 不成比例分析(信号检测)
计算每个不良事件的 PRR、ROR、IC 及 95% CI
应用信号检测标准
分类信号强度(强/中/弱/无)
|
Phase 3: FDA 标签安全信息
黑框警告、禁忌症
警告和注意事项、不良反应
药物相互作用、特殊人群
|
Phase 4: 基于机制的不良事件情境分析
基于靶点的 AE 预测(OpenTargets 安全性)
脱靶效应、ADMET 预测
药物类别效应比较
|
Phase 5: 比较安全性分析
与同类药物比较
识别独特信号与类别通用信号
头对头不成比例比较
|
Phase 6: 药物相互作用与风险因素
已知导致不良事件的 DDIs
药物基因组学风险因素(PharmGKB)
FDA PGx 生物标志物
|
Phase 7: 文献证据
PubMed 安全性研究、病例报告
OpenAlex 引文分析
预印本新出现信号(EuropePMC)
|
Phase 8: 风险评估与安全信号评分
计算安全信号评分(0-100)
对每个信号进行证据分级(T1-T4)
临床意义评估
|
Phase 9: 报告综合与建议
监测建议
风险缓解策略
完整性检查清单
将药物名称解析为 ChEMBL ID、DrugBank ID。获取作用机制、黑框警告状态、靶点和获批适应症。
OpenTargets_get_drug_chembId_by_generic_name, OpenTargets_get_drug_mechanisms_of_action_by_chemblId, OpenTargets_get_drug_blackbox_status_by_chembl_ID, drugbank_get_safety_by_drug_name_or_drugbank_id, drugbank_get_targets_by_drug_name_or_drugbank_id, OpenTargets_get_drug_indications_by_chemblId查询 FAERS 获取顶级不良事件、严重性分布、结果、人口统计学和死亡相关事件。按类型(死亡、住院、危及生命)筛选严重事件。获取 MedDRA 层级汇总。
FAERS_count_reactions_by_drug_event, FAERS_count_seriousness_by_drug_event, FAERS_count_outcomes_by_drug_event, FAERS_count_patient_age_distribution, FAERS_count_death_related_by_drug, FAERS_count_reportercountry_by_drug_event, FAERS_filter_serious_events, FAERS_rollup_meddra_hierarchy关键阶段。对于每个顶级不良事件(至少 15-20 个),计算 PRR、ROR、IC 及 95% CI。分类信号强度。按人口统计学对强信号进行分层。
FAERS_calculate_disproportionality, FAERS_stratify_by_demographicsPHASE_DETAILS.md提取黑框警告、禁忌症、警告/注意事项、不良反应、药物相互作用和特殊人群信息。注意:当某个部分不存在时,{error: {code: "NOT_FOUND"}} 是正常的。
FDA_get_boxed_warning_info_by_drug_name, FDA_get_contraindications_by_drug_name, FDA_get_warnings_by_drug_name, FDA_get_adverse_reactions_by_drug_name, FDA_get_drug_interactions_by_drug_name, FDA_get_pregnancy_or_breastfeeding_info_by_drug_name, FDA_get_geriatric_use_info_by_drug_name, FDA_get_pediatric_use_info_by_drug_name, FDA_get_pharmacogenomics_info_by_drug_name获取靶点安全性概况、OpenTargets 不良事件、ADMET 毒性预测(如果 SMILES 可用)和药物警告。
OpenTargets_get_target_safety_profile_by_ensemblID, OpenTargets_get_drug_adverse_events_by_chemblId, ADMETAI_predict_toxicity, ADMETAI_predict_CYP_interactions, OpenTargets_get_drug_warnings_by_chemblId使用 FAERS_compare_drugs 与同类药物进行头对头比较。汇总类别不良事件。识别类别通用信号与药物特异性信号。
FAERS_compare_drugs, FAERS_count_additive_adverse_reactions, FAERS_count_additive_seriousness_classification从 FDA 标签、DrugBank 和 DailyMed 中提取 DDIs。查询 PharmGKB 获取药物基因组学风险因素和剂量指南。检查 FDA PGx 生物标志物。
FDA_get_drug_interactions_by_drug_name, drugbank_get_drug_interactions_by_drug_name_or_id, DailyMed_parse_drug_interactions, PharmGKB_search_drugs, PharmGKB_get_drug_details, PharmGKB_get_dosing_guidelines, fda_pharmacogenomic_biomarkers搜索 PubMed、OpenAlex 和 EuropePMC 以获取安全性研究、病例报告和预印本。
PubMed_search_articles, openalex_search_works, EuropePMC_search_articles根据四个组成部分计算安全信号评分(0-100):FAERS 信号强度(0-35)、严重不良事件(0-30)、FDA 标签警告(0-25)、文献证据(0-10)。对每个信号进行 T1-T4 分级。评分细则见 PHASE_DETAILS.md。
生成全面的 Markdown 报告,包含执行摘要、所有阶段输出、监测建议、风险缓解策略、患者咨询要点和完整性检查清单。完整模板见 REPORT_TEMPLATE.md。
| 模式 | 描述 | 阶段 |
|---|---|---|
| 完整安全性概况 | 用于监管/安全性审查的全面报告 | 全部(0-9) |
| 特定不良事件调查 | "[药物] 是否会引起 [事件]?" | 0, 2, 3, 7 |
| 药物类别比较 | 比较 3-5 种药物的特定不良事件 | 0, 2, 5 |
| 新出现信号检测 | 筛查 FDA 标签中未包含的信号 | 1, 2, 3, 7 |
| PGx 风险评估 | 不良事件的遗传风险因素 | 0, 6 |
| 上市前评估 | FAERS 数据有限的新药 | 4, 7 |
OpenTargets_get_drug_chembId_by_generic_name 来解析FAERS_count_additive_adverse_reactions 进行汇总类别分析每周安装次数
122
代码库
GitHub 星标数
1.2K
首次出现
2026年2月19日
安全审计
安装于
codex118
gemini-cli117
opencode117
github-copilot116
kimi-cli113
amp113
Automated pipeline for detecting, quantifying, and contextualizing adverse drug event signals using FAERS disproportionality analysis, FDA label mining, mechanism-based prediction, and literature evidence. Produces a quantitative Safety Signal Score (0-100) for regulatory and clinical decision-making.
KEY PRINCIPLES :
Reference files (in this directory):
PHASE_DETAILS.md - Detailed tool calls, code examples, and output templates per phaseREPORT_TEMPLATE.md - Full report template and completeness checklistTOOL_REFERENCE.md - Tool parameter reference and fallback chainsQUICK_START.md - Quick examples and common drug namesApply when user asks:
Differentiation from tooluniverse-pharmacovigilance : This skill focuses specifically on signal detection and quantification using disproportionality analysis (PRR, ROR, IC) with statistical rigor, produces a quantitative Safety Signal Score (0-100) , and performs comparative safety analysis across drug classes.
Phase 0: Input Parsing & Drug Disambiguation
Parse drug name, resolve to ChEMBL ID, DrugBank ID
Identify drug class, mechanism, and approved indications
|
Phase 1: FAERS Adverse Event Profiling
Top adverse events by frequency
Seriousness and outcome distributions
Demographics (age, sex, country)
|
Phase 2: Disproportionality Analysis (Signal Detection)
Calculate PRR, ROR, IC with 95% CI for each AE
Apply signal detection criteria
Classify signal strength (Strong/Moderate/Weak/None)
|
Phase 3: FDA Label Safety Information
Boxed warnings, contraindications
Warnings and precautions, adverse reactions
Drug interactions, special populations
|
Phase 4: Mechanism-Based Adverse Event Context
Target-based AE prediction (OpenTargets safety)
Off-target effects, ADMET predictions
Drug class effects comparison
|
Phase 5: Comparative Safety Analysis
Compare to drugs in same class
Identify unique vs class-wide signals
Head-to-head disproportionality comparison
|
Phase 6: Drug-Drug Interactions & Risk Factors
Known DDIs causing AEs
Pharmacogenomic risk factors (PharmGKB)
FDA PGx biomarkers
|
Phase 7: Literature Evidence
PubMed safety studies, case reports
OpenAlex citation analysis
Preprint emerging signals (EuropePMC)
|
Phase 8: Risk Assessment & Safety Signal Score
Calculate Safety Signal Score (0-100)
Evidence grading (T1-T4) for each signal
Clinical significance assessment
|
Phase 9: Report Synthesis & Recommendations
Monitoring recommendations
Risk mitigation strategies
Completeness checklist
Resolve drug name to ChEMBL ID, DrugBank ID. Get mechanism of action, blackbox warning status, targets, and approved indications.
OpenTargets_get_drug_chembId_by_generic_name, OpenTargets_get_drug_mechanisms_of_action_by_chemblId, OpenTargets_get_drug_blackbox_status_by_chembl_ID, drugbank_get_safety_by_drug_name_or_drugbank_id, drugbank_get_targets_by_drug_name_or_drugbank_id, OpenTargets_get_drug_indications_by_chemblIdQuery FAERS for top adverse events, seriousness distribution, outcomes, demographics, and death-related events. Filter serious events by type (death, hospitalization, life-threatening). Get MedDRA hierarchy rollup.
FAERS_count_reactions_by_drug_event, FAERS_count_seriousness_by_drug_event, FAERS_count_outcomes_by_drug_event, FAERS_count_patient_age_distribution, FAERS_count_death_related_by_drug, FAERS_count_reportercountry_by_drug_event, FAERS_filter_serious_events, FAERS_rollup_meddra_hierarchyCRITICAL PHASE. For each top adverse event (at least 15-20), calculate PRR, ROR, IC with 95% CI. Classify signal strength. Stratify strong signals by demographics.
FAERS_calculate_disproportionality, FAERS_stratify_by_demographicsPHASE_DETAILS.md for full signal classification tableExtract boxed warnings, contraindications, warnings/precautions, adverse reactions, drug interactions, and special population info. Note: {error: {code: "NOT_FOUND"}} is normal when a section does not exist.
FDA_get_boxed_warning_info_by_drug_name, FDA_get_contraindications_by_drug_name, FDA_get_warnings_by_drug_name, FDA_get_adverse_reactions_by_drug_name, FDA_get_drug_interactions_by_drug_name, FDA_get_pregnancy_or_breastfeeding_info_by_drug_name, FDA_get_geriatric_use_info_by_drug_name, FDA_get_pediatric_use_info_by_drug_name, FDA_get_pharmacogenomics_info_by_drug_nameGet target safety profile, OpenTargets adverse events, ADMET toxicity predictions (if SMILES available), and drug warnings.
OpenTargets_get_target_safety_profile_by_ensemblID, OpenTargets_get_drug_adverse_events_by_chemblId, ADMETAI_predict_toxicity, ADMETAI_predict_CYP_interactions, OpenTargets_get_drug_warnings_by_chemblIdHead-to-head comparison with class members using FAERS_compare_drugs. Aggregate class AEs. Identify class-wide vs drug-specific signals.
FAERS_compare_drugs, FAERS_count_additive_adverse_reactions, FAERS_count_additive_seriousness_classificationExtract DDIs from FDA label, DrugBank, and DailyMed. Query PharmGKB for pharmacogenomic risk factors and dosing guidelines. Check FDA PGx biomarkers.
FDA_get_drug_interactions_by_drug_name, drugbank_get_drug_interactions_by_drug_name_or_id, DailyMed_parse_drug_interactions, PharmGKB_search_drugs, PharmGKB_get_drug_details, PharmGKB_get_dosing_guidelines, fda_pharmacogenomic_biomarkersSearch PubMed, OpenAlex, and EuropePMC for safety studies, case reports, and preprints.
PubMed_search_articles, openalex_search_works, EuropePMC_search_articlesCalculate Safety Signal Score (0-100) from four components: FAERS signal strength (0-35), serious AEs (0-30), FDA label warnings (0-25), literature evidence (0-10). Grade each signal T1-T4. See PHASE_DETAILS.md for scoring rubric.
Generate comprehensive markdown report with executive summary, all phase outputs, monitoring recommendations, risk mitigation strategies, patient counseling points, and completeness checklist. See REPORT_TEMPLATE.md for full template.
| Pattern | Description | Phases |
|---|---|---|
| Full Safety Profile | Comprehensive report for regulatory/safety reviews | All (0-9) |
| Specific AE Investigation | "Does [drug] cause [event]?" | 0, 2, 3, 7 |
| Drug Class Comparison | Compare 3-5 drugs for specific AE | 0, 2, 5 |
| Emerging Signal Detection | Screen for signals not in FDA label | 1, 2, 3, 7 |
| PGx Risk Assessment | Genetic risk factors for AEs | 0, 6 |
| Pre-Approval Assessment | New drugs with limited FAERS data | 4, 7 |
OpenTargets_get_drug_chembId_by_generic_name to resolveFAERS_count_additive_adverse_reactions for aggregate class analysisWeekly Installs
122
Repository
GitHub Stars
1.2K
First Seen
Feb 19, 2026
Security Audits
Gen Agent Trust HubPassSocketPassSnykWarn
Installed on
codex118
gemini-cli117
opencode117
github-copilot116
kimi-cli113
amp113
Excel财务建模规范与xlsx文件处理指南:专业格式、零错误公式与数据分析
44,500 周安装